NCT06133088: Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial. |
|
|
| Recruiting | 2 | 53 | RoW | dalpiciclib; fluvestrant; compound gossypol acetate tablets | Zhejiang Cancer Hospital | Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed | 12/24 | 08/25 | | |
NCT06308939: Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial |
|
|
| Not yet recruiting | 2 | 81 | RoW | Eribulin, eribulin mesylate, Sintilimab | Zhejiang Cancer Hospital | Metastatic Breast Cancer | 12/25 | 08/26 | | |
NCT05892354: Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy |
|
|
| Recruiting | N/A | 190 | RoW | Enteral immunonutrition, Standard enteral nutrition | First Affiliated Hospital of Guangxi Medical University, Guangdong Provincial People's Hospital, Zhejiang Cancer Hospital, Zhejiang Provincial People's Hospital, Fujian Cancer Hospital, Fujian Provincial Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanchang University, Second Affiliated Hospital of Nanchang University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Qingdao Central Hospital, Huizhou Municipal Central Hospital, Haikou People's Hospital, The Second Affiliated Hospital of Hainan Medical University, Zhejiang Provincial Tongde Hospital, Guilin Medical University, China, Liuzhou Workers Hospital, Wuzhou Red Cross Hospital, Red Cross Hospital of Yulin City, First People's Hospital of Yulin, Hainan Cancer Hospital | Locally Advanced Nasopharyngeal Carcinoma | 04/25 | 04/27 | | |
